[Formation of virus-like particles by HIV-1 Gag proteins, expressed by a recombinant vaccinia virus]

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

[Formation of virus-like particles by HIV-1 Gag proteins, expressed by a recombinant vaccinia virus]

Mol Biol (Mosk). 1990 Nov-Dec;24(6):1666-74. Unique Identifier : AIDSLINE MED/91246152
Vzorov AN; Tentsov IuIu; Grigor'ev VB; Shulenin SA; Garaev MM; Bogdan OP; Bukrinskaia AG

Abstract: Monkey kidney cells CV-1 were infected with recombinant vaccinia virus carrying HIV-1 gag gene with a deletion of 230 nucleotide pairs from the 3'-terminus. The main gene product detected in the lysates of infected cells was the gag precursor rp50. The protein was accumulated on the cell membranes suggesting that it had a myristylated N-terminus, and was cleaved by a recombinant virus specific protease with the formation of two proteins, p17 and p24 corresponding in molecular masses to mature gag proteins. Virus-like particles similar to immature HIV virions were budding from the surface of infected cells. They look like the ring of optically dense material covered with a lipid bilayer, of the same size (100-120 nm) and of the same density in a sucrose gradient (1.16-1.18 g/ml) as HIV-1 virions. The particles contained rp50 and cellular heterogeneous RNA. Thus, the unprocessed gag precursor with deleted 77 amino acid residues from the C-terminus is able to form virus-like particles in the absence of env proteins and virus-specific RNA, and these particles are budding from the cell surface. The question about the use of extracellular Gag-particles for AIDS diagnostic work and construction of vaccines is discussed.

Keywords: Blotting, Northern Cell Line Electrophoresis, Polyacrylamide Gel English Abstract *Gene Expression Regulation, Viral Gene Products, gag/*GENETICS Hydrolysis HIV-1/*GENETICS Microscopy, Electron Microscopy, Fluorescence Nucleic Acid Hybridization Recombination, Genetic RNA, Viral/ANALYSIS Vaccinia Virus/*GENETICS *Virion JOURNAL ARTICLE
910930
M9190689

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .